Knowledge, attitudes and practices of business travelers regarding influenza and the use of antiviral medicationArchived
This descriptive study evaluated knowledge, attitudes and practices of Swiss business travelers with regards to influenza and the use of anti-viral medication.
Global Review of recent Antiviral Resistance dataArchived
Each year in February WHO convenes a meeting with advisers from the WHO Influenza Collaborating Centres and Essential Reference laboratories in order to achieve consensus and advise WHO on the optimal formulation of seasonal influenza vaccines for the next influenza season.
Two evaluations of the response to the 2009 Pandemic in Spain: Surveillance and Vaccines and antiviralsArchived
Two official evaluations have been made by the national Ministry of Health of Spain of their country’s response to the 2009 influenza pandemic. The reviews focused on two particular topics - Surveillance and Vaccines and Antivirals.
How effective were neuraminidase inhibitors during the 2009 pandemic?Archived
This systematic review and meta-analysis of observational data from an established group of specialists assessed treatment outcomes for all three neuraminidase inhibitors (NAIs); oseltamivir, zanamivir and peramivir given to hospitalised patients with influenza A(H1N1)pdm09 during the 2009 pandemic.
New and updated evaluations of neuraminidase inhibitors for preventing and treating influenza published
This evaluated patients admitted to hospital with laboratory-confirmed or clinically diagnosed influenza A H1N1pdm09 virus infection.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).